These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31718606)

  • 1. Determination of the androgen receptor status of circulating tumour cells in metastatic breast cancer patients.
    Krawczyk N; Neubacher M; Meier-Stiegen F; Neubauer H; Niederacher D; Ruckhäberle E; Mohrmann S; Hoffmann J; Kaleta T; Banys-Paluchowski M; Reinecke P; Esposito I; Janni W; Fehm T
    BMC Cancer; 2019 Nov; 19(1):1101. PubMed ID: 31718606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor expression on circulating tumor cells in metastatic breast cancer.
    Fujii T; Reuben JM; Huo L; Espinosa Fernandez JR; Gong Y; Krupa R; Suraneni MV; Graf RP; Lee J; Greene S; Rodriguez A; Dugan L; Louw J; Lim B; Barcenas CH; Marx AN; Tripathy D; Wang Y; Landers M; Dittamore R; Ueno NT
    PLoS One; 2017; 12(9):e0185231. PubMed ID: 28957377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer.
    de Kruijff IE; Sieuwerts AM; Onstenk W; Jager A; Hamberg P; de Jongh FE; Smid M; Kraan J; Timmermans MA; Martens JWM; Sleijfer S
    Int J Cancer; 2019 Aug; 145(4):1083-1089. PubMed ID: 30761532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation.
    Frithiof H; Welinder C; Larsson AM; Rydén L; Aaltonen K
    J Transl Med; 2015 Apr; 13():126. PubMed ID: 25896421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program.
    Müller V; Banys-Paluchowski M; Friedl TWP; Fasching PA; Schneeweiss A; Hartkopf A; Wallwiener D; Rack B; Meier-Stiegen F; Huober J; Rübner M; Hoffmann O; Müller L; Janni W; Wimberger P; Jäger B; Pantel K; Riethdorf S; Harbeck N; Fehm T;
    ESMO Open; 2021 Dec; 6(6):100299. PubMed ID: 34839105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial.
    Gennari A; Foca F; Zamarchi R; Rocca A; Amadori D; De Censi A; Bologna A; Cavanna L; Gianni L; Scaltriti L; Rossi E; Facchinetti A; Martini V; Bruzzi P; Nanni O
    Breast Cancer Res Treat; 2020 May; 181(1):61-68. PubMed ID: 32200486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.
    McDaniel AS; Ferraldeschi R; Krupa R; Landers M; Graf R; Louw J; Jendrisak A; Bales N; Marrinucci D; Zafeiriou Z; Flohr P; Sideris S; Crespo M; Figueiredo I; Mateo J; de Bono JS; Dittamore R; Tomlins SA; Attard G
    BJU Int; 2017 Nov; 120(5B):E30-E44. PubMed ID: 27539393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.
    Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP
    Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
    Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z
    BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis.
    Ramirez AB; Bhat R; Sahay D; De Angelis C; Thangavel H; Hedayatpour S; Dobrolecki LE; Nardone A; Giuliano M; Nagi C; Rimawi M; Osborne CK; Lewis MT; Stilwell JL; Kaldjian EP; Schiff R; Trivedi MV
    BMC Cancer; 2019 Mar; 19(1):220. PubMed ID: 30871481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
    Schramm A; Friedl TW; Schochter F; Scholz C; de Gregorio N; Huober J; Rack B; Trapp E; Alunni-Fabbroni M; Müller V; Schneeweiss A; Pantel K; Meier-Stiegen F; Hartkopf A; Taran FA; Wallwiener D; Janni W; Fehm T
    Arch Gynecol Obstet; 2016 Feb; 293(2):271-81. PubMed ID: 26354331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.
    Somlo G; Lau SK; Frankel P; Hsieh HB; Liu X; Yang L; Krivacic R; Bruce RH
    Breast Cancer Res Treat; 2011 Jul; 128(1):155-63. PubMed ID: 21499685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.
    Deng G; Herrler M; Burgess D; Manna E; Krag D; Burke JF
    Breast Cancer Res; 2008; 10(4):R69. PubMed ID: 18687126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
    Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
    PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer.
    Nanou A; Zeune LL; Bidard FC; Pierga JY; Terstappen LWMM
    Breast Cancer Res; 2020 Aug; 22(1):86. PubMed ID: 32787900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
    Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS
    Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
    Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
    BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.
    Beije N; Onstenk W; Kraan J; Sieuwerts AM; Hamberg P; Dirix LY; Brouwer A; de Jongh FE; Jager A; Seynaeve CM; Van NM; Foekens JA; Martens JW; Sleijfer S
    Neoplasia; 2016 Nov; 18(11):647-653. PubMed ID: 27764697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest.
    Liu HE; Vuppalapaty M; Hoerner CR; Bergstrom CP; Chiu M; Lemaire C; Che J; Kaur A; Dimmick A; Liu S; Metzner TJ; Araya M; Crouse S; Sprenger-Haussels M; Schlumpberger M; Leppert JT; Hauch S; Sollier E; Fan AC
    BMC Cancer; 2024 Apr; 24(1):482. PubMed ID: 38627648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.